Risks and capability
Four synthetic biology risk objects open the portfolio. Order carries no rank. Each is read across driver, exposure, vulnerability, capacity, cascade and consequence.
目次
- ·Edition home
- ·Executive summary
- 1Synthetic biology is a build capability and a governance test
- 2Key findings
- 3Systems and sectors at baseline
- 4Risks and capability
- 5Design capability outpaces screening and oversight
- 6Readings from the other desks
- 7The 2027 agenda
- 8Systems in depth
- A方法論
- BData appendix
- CReferences and record
- ·Complete edition, for print
4.1Risk objects
Each risk is read across the chain from hazard to consequence, with its status and evidence-quality level.
InferredEQL 3RSK-XT04-SEC-001
Design capability outpaces screening
InferredEQL 3RSK-XT04-GOV-002
Fragmented and shifting oversight
Expert inputEQL 2RSK-XT04-SUP-003
Manufacturing base thinner than headlines
InferredEQL 2RSK-XT04-ENV-004
Release and novel-organism questions
4.2Capability ladder
Existence is not readiness. Each of the fifteen capability functions is placed on the ladder by the strongest public evidence for synthetic biology at the global level.
| 機能 | Rung | レベル | Strongest public evidence at baseline |
|---|---|---|---|
| Prevention and mitigation | EXISTS | screening guidance and dual-use frameworks published212531 | |
| Monitoring and observation | LISTED | no common tracker of synthesis orders or screening coverage | |
| 早期警報 | LISTED | horizon scanning exists under the CBD but is scaled back20 | |
| Preparedness and planning | EXISTS | US commission report, EU proposal and OECD papers141822 | |
| Redundancy and reserves | LISTED | manufacturing capacity and reserves not counted | |
| 対応 | LISTED | no tested response to a misuse event described in the sources | |
| Continuity of critical services | LISTED | not reviewed | |
| 復旧 | LISTED | not applicable at baseline; no event to recover from | |
| Adaptation | EXISTS | anticipatory governance principles in OECD work1819 | |
| 社会保障 | LISTED | not applicable at baseline | |
| 金融と保険 | LISTED | public and private investment not on a common basis | |
| Institutional coordination | EXISTS | WHO, CBD and OECD processes182021 | |
| Technical infrastructure | EXISTS | bioindustrial institute and planning awards2324 | |
| 労働力 | LISTED | skills gaps reported in policy documents; no figure bound | |
| Research capacity | ADEQUATE | strong peer-reviewed base1467 | |
| A capability listed in policy is not a tested one; each rung is the strongest public evidence at baseline. | |||
Notes
Numbers are the edition’s reference numbers, so a note reads the same in every chapter. The full list, with every source and its licence, is in Annex C. Annex C, references
- 7Watson, J.L. et al., De novo design of protein structure and function with RFdiffusion, Nature 620, 1089 to 1100, 2023 (record read via Europe PMC). Springer Nature, London. Observation year 2023. Accessed 2026-11-03.back
- 13Strengthening nucleic acid biosecurity screening against generative protein design tools, Science 390 (6768), 82 to 87, 2025 (record read via Europe PMC; abstract only; no method detail used). American Association for the Advancement of Science, Washington. Observation year 2025. Accessed 2026-11-03.back
- 25National Science and Technology Council, Fast Track Action Committee on Synthetic Nucleic Acid Procurement Screening (ed.), Framework for Nucleic Acid Synthesis Screening (version 1 April 2024, revised September 2024; framework document read). Office of Science and Technology Policy, Washington. Observation year 2024. Accessed 2026-11-05.back
- 31International Gene Synthesis Consortium (ed.), Harmonized Screening Protocol v3.1, 1 June 2026 (document read; common sequence and customer screening practice of IGSC members). IGSC. Observation year 2026. Accessed 2026-11-05.back
- 32Department for Science, Innovation and Technology (ed.), UK screening guidance on synthetic nucleic acids for users and providers, 8 October 2024 (guidance page read). DSIT, London. Observation year 2024. Accessed 2026-11-05.back
- 20Secretariat of the Convention on Biological Diversity (ed.), Synthetic biology (programme page; decisions X/13 to 16/21; AHTEG; horizon scanning; thematic action plan). CBD Secretariat, Montreal. Observation year 2026. Accessed 2026-11-03.back
- 22Baker McKenzie (ed.), EU Biotech Act unveiled: Commission proposal to turn Europe into a biotech powerhouse (law firm summary, 19 December 2025; proposal of 16 December 2025; health focus; investment pilot with the European Investment Bank Group; 12-month certificate extension; biodefence measures; second act expected in Q3 2026). Secondary source, not the Commission text. Observation year 2025. Accessed 2026-11-03.back
- 26The White House (ed.), Executive Order 14292 of 5 May 2025, Improving the Safety and Security of Biological Research, Federal Register 2025-08266, 8 May 2025 (text read; section 4(b) gives OSTP 90 days to revise or replace the 2024 Framework for Nucleic Acid Synthesis Screening). Office of the Federal Register, Washington. Observation year 2025. Accessed 2026-11-05.back
- 27Congressional Research Service (ed.), Artificial Intelligence and Biosecurity Issues, CRS In Focus IF13269, 16 July 2026, updated 3 August and 15 September 2026 (all three versions read; the July version states that CRS could not determine whether the 2024 policy and the 2024 screening framework had been revised or replaced; the September update states that a July 2026 policy replaced the 2024 dual-use research policy and that OSTP had not updated the 2024 screening framework). Library of Congress, Washington. Observation year 2026. Accessed 2026-11-05.back
- 18OECD (ed.), Anticipatory governance for responsible innovation in synthetic biology, OECD Science, Technology and Industry Policy Papers No. 193, 21 May 2026 (record read via a bibliographic database; abstract only). OECD Publishing, Paris. Observation year 2026. Accessed 2026-11-03.back
- 21World Health Organization (ed.), Global guidance framework for the responsible use of the life sciences: mitigating biorisks and governing dual-use research (publication page, 13 September 2022). WHO, Geneva. Observation year 2022. Accessed 2026-11-03.back
- 16Twist Bioscience Corporation (ed.), Form 8-K exhibit 99.1, results for the fiscal third quarter ended 30 June 2026 (company filing; revenue USD 118.4 million; nine months USD 332.8 million; fiscal 2026 guidance USD 456 to 457 million; company statements and guidance are weak evidence). US Securities and Exchange Commission, Washington. Observation year 2026. Accessed 2026-11-03.back
- 17Ginkgo Bioworks Holdings, Inc. (ed.), Form 8-K exhibit 99.1, fourth quarter and full year 2025 results (company filing of 26 February 2026; revenue USD 170.155 million against USD 227.043 million; net loss USD 312.763 million; company statements are weak evidence). US Securities and Exchange Commission, Washington. Observation year 2025. Accessed 2026-11-03.back
- 24US Manufacturing Program (ed.), Bioindustrial (programme topic page; Distributed Bioindustrial Manufacturing Program awards announced 10 July to 13 September 2024; 25 awards; USD 42 million cumulative). Manufacturing USA, Gaithersburg. Observation year 2024. Accessed 2026-11-03.back
- 23BioMADE (ed.), DoD approves USD 87 million for newest bioindustrial manufacturing innovation institute (news page; seven years; the page shows Oct 20 and a 2023 footer, the press release is dated 2020 in search listings). BioMADE, Saint Paul. Observation year 2020. Accessed 2026-11-03.back
- 1Robertson, W.E. et al., Escherichia coli with a 57-codon genetic code, Science 390 (6771), eady4368, published 23 October 2025 (record read via PubMed, PMID 40743368; the record gives a 4 megabase synthetic genome and six replaced sense codons). American Association for the Advancement of Science, Washington. Observation year 2025. Accessed 2026-11-03.back
- 11Kyrou, K. et al., A CRISPR-Cas9 gene drive targeting doublesex causes complete population suppression in caged Anopheles gambiae mosquitoes, Nature Biotechnology 36, 1062 to 1066, 2018 (record read via Europe PMC; laboratory cages only). Springer Nature, London. Observation year 2018. Accessed 2026-11-03.back
- 12Confronting risks of mirror life, Science 386, 1351 to 1353, 2024 (record read via Europe PMC; the record gives only a one-line abstract calling for broad discussion). American Association for the Advancement of Science, Washington. Observation year 2024. Accessed 2026-11-03.back
- 35Secretariat of the Convention on Biological Diversity (ed.), The Cartagena Protocol on Biosafety to the Convention on Biological Diversity (protocol page read; adopted 29 January 2000; in force since 11 September 2003; governs living modified organisms). CBD Secretariat, Montreal. Observation year 2000. Accessed 2026-11-05.back
- 14Congressional Research Service (ed.), National Security Commission on Emerging Biotechnology: Final Report and Options for Congress, CRS Insight IN12546, 17 April 2025 (report of 8 April 2025; 49 recommendations; at least USD 15 billion over five years; National Biotechnology Coordination Office). Library of Congress, Washington. Observation year 2025. Accessed 2026-11-03.back
- 19OECD (ed.), Synthetic biology, AI and automation: a forward-looking technology assessment, OECD Science, Technology and Industry Policy Papers No. 187, 4 December 2025 (record read via a bibliographic database; abstract only). OECD Publishing, Paris. Observation year 2025. Accessed 2026-11-03.back
- 4Debugging and consolidating multiple synthetic chromosomes reveals combinatorial genetic interactions, Cell 186 (24), 5220 to 5236, 2023 (record read via Europe PMC: 6.5 synthetic chromosomes in one strain; over half of the Sc2.0 genome). Cell Press, Cambridge, Massachusetts. Observation year 2023. Accessed 2026-11-03.back
- 6Nielsen, A.A.K. et al., Genetic circuit design automation, Science 352 (6281), 2016 (record read via Europe PMC: 60 circuits; 45 correct in all output states; 92% of output states as predicted). American Association for the Advancement of Science, Washington. Observation year 2016. Accessed 2026-11-03.back